Levofloxacin Efflux and smeD in Clinical Isolates of Stenotrophomonas maltophilia

So Young Chong, Kyungwon Lee, Hae Sun Chung, Seong Geun Hong, Younghee Suh, Yunsop Chong

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Trimethoprim-sulfamethoxazole is the first-line antimicrobial combination for Stenotrophomonas maltophilia infections. However, allergy or intolerance and increasing resistance limit the use of trimethoprim-sulfamethoxazole. Quinolones can be used as an alternative therapeutic option, but resistance can emerge rapidly during therapy. We analyzed the contribution of SmeABC and SmeDEF efflux pumps to levofloxacin resistance in clinical isolates of S. maltophilia. Nonduplicate clinical isolates of S. maltophilia were collected in 2010 from 11 university hospitals (n = 102). Fifty-five levofloxacin nonsusceptible (minimum inhibitory concentration [MIC] ≥4 μg/ml) and 47 susceptible (MIC ≤2 μg/ml) isolates were tested for efflux pump overexpression. Real-time reverse transcription-PCR was performed for amplification and quantification of smeB, smeC, smeD, and smeF mRNA. To determine which antimicrobials were affected by smeD overexpression, the growth rates of a levofloxacin-susceptible S. maltophilia isolate were compared by measuring absorbance of antimicrobial-supplemented Luria-Bertani broth (LB) cultures with or without triclosan. Significant relationships between sme gene overexpression and resistance were observed for smeD against levofloxacin, smeC and smeF against ceftazidime, and smeC against ticarcillin-clavulanate. The mean MICs of moxifloxacin and tigecycline did not significantly differ for isolates with or without overexpression of smeB, smeC, and smeF, but were significantly higher for isolates with smeD overexpression. The mean MICs of amikacin were significantly higher for smeC or smeF overexpressing isolates. Increased growth of a levofloxacin-susceptible isolate was observed in LB with 1/2 MIC levofloxacin in the presence of triclosan. These data suggest that the expression of smeD plays a role in levofloxacin resistance in S. maltophilia.

Original languageEnglish
Pages (from-to)163-168
Number of pages6
JournalMicrobial Drug Resistance
Volume23
Issue number2
DOIs
Publication statusPublished - 2017 Mar 1

Fingerprint

Stenotrophomonas maltophilia
Levofloxacin
Microbial Sensitivity Tests
Triclosan
Sulfamethoxazole Drug Combination Trimethoprim
Ticarcillin
Clavulanic Acid
Ceftazidime
Amikacin
Quinolones
Growth
Reverse Transcription
Hypersensitivity
Polymerase Chain Reaction
Messenger RNA
Therapeutics
Infection

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Immunology
  • Pharmacology
  • Microbiology (medical)

Cite this

Chong, So Young ; Lee, Kyungwon ; Chung, Hae Sun ; Hong, Seong Geun ; Suh, Younghee ; Chong, Yunsop. / Levofloxacin Efflux and smeD in Clinical Isolates of Stenotrophomonas maltophilia. In: Microbial Drug Resistance. 2017 ; Vol. 23, No. 2. pp. 163-168.
@article{24b6b946b39e4747929f4afc3343b452,
title = "Levofloxacin Efflux and smeD in Clinical Isolates of Stenotrophomonas maltophilia",
abstract = "Trimethoprim-sulfamethoxazole is the first-line antimicrobial combination for Stenotrophomonas maltophilia infections. However, allergy or intolerance and increasing resistance limit the use of trimethoprim-sulfamethoxazole. Quinolones can be used as an alternative therapeutic option, but resistance can emerge rapidly during therapy. We analyzed the contribution of SmeABC and SmeDEF efflux pumps to levofloxacin resistance in clinical isolates of S. maltophilia. Nonduplicate clinical isolates of S. maltophilia were collected in 2010 from 11 university hospitals (n = 102). Fifty-five levofloxacin nonsusceptible (minimum inhibitory concentration [MIC] ≥4 μg/ml) and 47 susceptible (MIC ≤2 μg/ml) isolates were tested for efflux pump overexpression. Real-time reverse transcription-PCR was performed for amplification and quantification of smeB, smeC, smeD, and smeF mRNA. To determine which antimicrobials were affected by smeD overexpression, the growth rates of a levofloxacin-susceptible S. maltophilia isolate were compared by measuring absorbance of antimicrobial-supplemented Luria-Bertani broth (LB) cultures with or without triclosan. Significant relationships between sme gene overexpression and resistance were observed for smeD against levofloxacin, smeC and smeF against ceftazidime, and smeC against ticarcillin-clavulanate. The mean MICs of moxifloxacin and tigecycline did not significantly differ for isolates with or without overexpression of smeB, smeC, and smeF, but were significantly higher for isolates with smeD overexpression. The mean MICs of amikacin were significantly higher for smeC or smeF overexpressing isolates. Increased growth of a levofloxacin-susceptible isolate was observed in LB with 1/2 MIC levofloxacin in the presence of triclosan. These data suggest that the expression of smeD plays a role in levofloxacin resistance in S. maltophilia.",
author = "Chong, {So Young} and Kyungwon Lee and Chung, {Hae Sun} and Hong, {Seong Geun} and Younghee Suh and Yunsop Chong",
year = "2017",
month = "3",
day = "1",
doi = "10.1089/mdr.2015.0228",
language = "English",
volume = "23",
pages = "163--168",
journal = "Microbial Drug Resistance",
issn = "1076-6294",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

Levofloxacin Efflux and smeD in Clinical Isolates of Stenotrophomonas maltophilia. / Chong, So Young; Lee, Kyungwon; Chung, Hae Sun; Hong, Seong Geun; Suh, Younghee; Chong, Yunsop.

In: Microbial Drug Resistance, Vol. 23, No. 2, 01.03.2017, p. 163-168.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Levofloxacin Efflux and smeD in Clinical Isolates of Stenotrophomonas maltophilia

AU - Chong, So Young

AU - Lee, Kyungwon

AU - Chung, Hae Sun

AU - Hong, Seong Geun

AU - Suh, Younghee

AU - Chong, Yunsop

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Trimethoprim-sulfamethoxazole is the first-line antimicrobial combination for Stenotrophomonas maltophilia infections. However, allergy or intolerance and increasing resistance limit the use of trimethoprim-sulfamethoxazole. Quinolones can be used as an alternative therapeutic option, but resistance can emerge rapidly during therapy. We analyzed the contribution of SmeABC and SmeDEF efflux pumps to levofloxacin resistance in clinical isolates of S. maltophilia. Nonduplicate clinical isolates of S. maltophilia were collected in 2010 from 11 university hospitals (n = 102). Fifty-five levofloxacin nonsusceptible (minimum inhibitory concentration [MIC] ≥4 μg/ml) and 47 susceptible (MIC ≤2 μg/ml) isolates were tested for efflux pump overexpression. Real-time reverse transcription-PCR was performed for amplification and quantification of smeB, smeC, smeD, and smeF mRNA. To determine which antimicrobials were affected by smeD overexpression, the growth rates of a levofloxacin-susceptible S. maltophilia isolate were compared by measuring absorbance of antimicrobial-supplemented Luria-Bertani broth (LB) cultures with or without triclosan. Significant relationships between sme gene overexpression and resistance were observed for smeD against levofloxacin, smeC and smeF against ceftazidime, and smeC against ticarcillin-clavulanate. The mean MICs of moxifloxacin and tigecycline did not significantly differ for isolates with or without overexpression of smeB, smeC, and smeF, but were significantly higher for isolates with smeD overexpression. The mean MICs of amikacin were significantly higher for smeC or smeF overexpressing isolates. Increased growth of a levofloxacin-susceptible isolate was observed in LB with 1/2 MIC levofloxacin in the presence of triclosan. These data suggest that the expression of smeD plays a role in levofloxacin resistance in S. maltophilia.

AB - Trimethoprim-sulfamethoxazole is the first-line antimicrobial combination for Stenotrophomonas maltophilia infections. However, allergy or intolerance and increasing resistance limit the use of trimethoprim-sulfamethoxazole. Quinolones can be used as an alternative therapeutic option, but resistance can emerge rapidly during therapy. We analyzed the contribution of SmeABC and SmeDEF efflux pumps to levofloxacin resistance in clinical isolates of S. maltophilia. Nonduplicate clinical isolates of S. maltophilia were collected in 2010 from 11 university hospitals (n = 102). Fifty-five levofloxacin nonsusceptible (minimum inhibitory concentration [MIC] ≥4 μg/ml) and 47 susceptible (MIC ≤2 μg/ml) isolates were tested for efflux pump overexpression. Real-time reverse transcription-PCR was performed for amplification and quantification of smeB, smeC, smeD, and smeF mRNA. To determine which antimicrobials were affected by smeD overexpression, the growth rates of a levofloxacin-susceptible S. maltophilia isolate were compared by measuring absorbance of antimicrobial-supplemented Luria-Bertani broth (LB) cultures with or without triclosan. Significant relationships between sme gene overexpression and resistance were observed for smeD against levofloxacin, smeC and smeF against ceftazidime, and smeC against ticarcillin-clavulanate. The mean MICs of moxifloxacin and tigecycline did not significantly differ for isolates with or without overexpression of smeB, smeC, and smeF, but were significantly higher for isolates with smeD overexpression. The mean MICs of amikacin were significantly higher for smeC or smeF overexpressing isolates. Increased growth of a levofloxacin-susceptible isolate was observed in LB with 1/2 MIC levofloxacin in the presence of triclosan. These data suggest that the expression of smeD plays a role in levofloxacin resistance in S. maltophilia.

UR - http://www.scopus.com/inward/record.url?scp=85015099541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015099541&partnerID=8YFLogxK

U2 - 10.1089/mdr.2015.0228

DO - 10.1089/mdr.2015.0228

M3 - Article

C2 - 27294684

AN - SCOPUS:85015099541

VL - 23

SP - 163

EP - 168

JO - Microbial Drug Resistance

JF - Microbial Drug Resistance

SN - 1076-6294

IS - 2

ER -